<DOC>
	<DOCNO>NCT00031824</DOCNO>
	<brief_summary>RATIONALE : Hydroxychloroquine may decrease immune response effective treat chronic graft-versus-host disease . It yet know standard therapy graft-versus-host disease effective without hydroxychloroquine . PURPOSE : Randomized phase III trial compare effectiveness standard therapy alone standard therapy plus hydroxychloroquine treating patient newly diagnose chronic graft-versus-host disease .</brief_summary>
	<brief_title>Hydroxychloroquine Treating Patients With Newly Diagnosed Chronic Graft-Versus-Host Disease</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare efficacy prednisone cyclosporine v without hydroxychloroquine patient newly diagnose extensive chronic graft-versus-host disease ( GVHD ) . Secondary - Compare event-free overall survival patient treat regimen . - Compare health-related quality life , include longitudinal change magnitude persistent disability , patient treat regimen . - Correlate cytokine level T-helper cell subtypes chronic GVHD activity response patient treat regimen . - Correlate whole blood hydroxychloroquine level response toxicity patient treat regimen . OUTLINE : This randomize , placebo-controlled , double-blind , multicenter study . Patients randomize one two treatment arm . Patients may receive standard therapy comprise prednisone orally IV 2-3 time daily every day cyclosporine orally IV twice daily tacrolimus orally twice daily IV continuous infusion randomization . Patients receive cyclosporine tacrolimus prior randomization may receive cyclosporine tacrolimus randomization accord institutional preference . - Arm I : Within 10-14 day begin therapy prednisone cyclosporine tacrolimus , patient receive oral hydroxychloroquine twice daily . - Arm II : Patients receive standard therapy prednisone cyclosporine tacrolimus arm I oral placebo twice daily . In arm , treatment continue 9 month absence disease progression unacceptable toxicity . Patients response 2 month therapy take study . Quality life assess baseline , 1 month , 9 month , 1 year . Patients follow every month 3 month 9 month . PROJECTED ACCRUAL : A total 232 patient ( 116 per treatment arm ) accrue study within 3.6 year .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Hydroxychloroquine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirmed* newly diagnose extensive chronic graftversushost disease ( GVHD ) ≥ 1 organ system ( e.g. , lip , skin , liver ) document follow : Clinicopathologic feature GVHD , include involvement follow organ system : Skin change Oral change Hepatic involvement Gastrointestinal involvement Sicca syndrome Pulmonary involvement Myofascial Skeletal Other inflammatory condition ( e.g. , myositis , arthritis , polyserositis , unexplained pericardial , pleural , peritoneal effusion ) Autoantibodies Extent disease , define accord follow classification : Limited chronic GVHD , define 1 following : Localized skin involvement and/or liver dysfunction Involvement 1 target organ Extensive chronic GVHD , define 1 following : Generalized skin involvement ≥ 50 % body surface area Localized skin involvement and/or liver dysfunction AND ≥ 1 following : Liver histology show chronic aggressive hepatitis , bridge necrosis , cirrhosis Eye involvement ( Schirmer 's test &lt; 5 mm wet ) Involvement minor salivary gland oral mucosa lip biopsy Involvement target organ Involvement ≥ 2 target organ Timing onset , include onset follow type : Progressive onset define , evolve directly acute GVHD , commonly development typical manifestation oral skin lichenoid change sclerodermatous skin change Quiescent onset , define develop resolution acute GVHD De novo onset , define develop prior history acute GVHD Must ≥ 1 typical clinical manifestation chronic GVHD differs acute GVHD ( e.g. , rash , anorexia , nausea , emesis , diarrhea , abdominal pain , cholestasis ) Symptoms acute GVHD allow time diagnosis chronic GVHD Prior allogeneic bone marrow , peripheral blood stem cell , cord blood transplantation family member unrelated donor malignancy require NOTE : *Histologic confirmation may `` consistent GVHD '' PATIENT CHARACTERISTICS : Age : 1 29 Performance status : Lansky 50100 % OR Karnofsky 50100 % Life expectancy : At least 2 month Hematopoietic : Absolute neutrophil count ≥ 1,000/mm^3 , unless due chronic GVHD ( i.e. , autoimmune neutropenia bone marrow suppression ) Hepatic : See Disease Characteristics Renal : Creatinine &lt; 1.5 time upper limit normal OR Creatinine clearance ≥ 60 mL/min Other : Not pregnant Negative pregnancy test Fertile patient must use effective contraception 3 month study participation No lysosomal storage disorder No uncontrolled infection ( e.g. , persistent bacterial , fungal , viral infection despite appropriate antimicrobial therapy ) No G6PD deficiency No history psoriasis porphyria No hypersensitivity 4aminoquinolines No prior retinal visual field change due 4aminoquinolines PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics No concurrent daclizumab infliximab No concurrent thalidomide Chemotherapy : Not specify Endocrine therapy : Prior topical steroid treatment extensive chronic GVHD allow Prior adjustment prednisone dose allow do reversal taper Prior steroid ( prednisone ≤ 1 mg/kg/day ( equivalent ) symptom management 1 week study entry allow Concurrent steroid treatment and/or prophylaxis acute GVHD allow prednisone dose ≤ 2 mg/kg/day ( equivalent ) Concurrent topical steroid allow Radiotherapy : Not specify Surgery : Not specify Other : No prior treatment extensive chronic GVHD except follow : Topical treatment ( e.g. , tacrolimus ointment pimecrolimus cream ) Adjustments cyclosporine tacrolimus dos GVHD prophylaxis treatment acute GVHD Concurrent cyclosporine tacrolimus allow Cyclosporine must start study entry No concurrent systemic topical immunosuppressant , include follow : Azathioprine Mycophenolate mofetil Psoralenultraviolet light therapy Photopheresis No administration follow 1 hour 2 hour study drug administration : Antacids Sucralfate Cholestyramine Bicarbonate</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>29 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>graft versus host disease</keyword>
</DOC>